Clinical trial
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally…
NCT00005958 · Amgen, Industry · Unknown status
Key facts
| NCT number | NCT00005958 |
|---|---|
| Title | Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer |
| Official title | Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim |
| Lead sponsor | Amgen, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, docetaxel, gemcitabine hydrochloride |
| Start date | Oct 1, 1999 |
| First posted | Apr 20, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: